<< Вернуться к списку статей журнала

Том 17 №2 2015 год - Нефрология и диализ

Применение циклоспорина а для лечения нефротических типов хронических гломерулонефритов - болезни минимальных изменений и фокального сегментарного гломерулосклероза

Руденко Е.В. Томилина Н.А. Захарова Е.В.

Аннотация: В настоящее время применение Циклоспорина А (ЦcА) является признанным методом лечения нефротических вариантов гломерулонефритов (ГН), в основе которых лежит повреждение подоцитов. Этот препарат занял общепризнанное место в лечении БМИ и ФСГС, при которых он используется чаще всего в комбинации с кортикостероидами (ГКС) и рекомендуется, главным образом, при ГКС-рефрактерности либо при непереносимости или наличии противопоказаний к ГКС. Кроме того, применение ЦсА предлагается для поддержания ремиссии нефротического синдрома (НС), достигнутой ГКС-терапией, а также для профилактики и/или лечения рецидивов заболевания. В обзоре представлены общие сведения и механизмы действия ЦсА на Т-лимфоциты (иммуносупрессивный эффект), на неиммунные клетки и непосредственно на подоцит (антипротеинурический эффект). Считается, что эффективность ЦсА при лечении НС у пациентов с ФСГС связана с ингибицией кальцинейрин-обусловленного дефосфорилирования и уменьшением распада белка синаптоподина, результатом чего является стабилизация подоцитарного актинового цитоскелета, повреждаемого, в частности, факторами проницаемости, особенно при наличии определенной генетической предрасположенности. В данной статье приводится обзор литературы по применению ЦсА в лечении нефротических видов гломерулонефритов - болезни минимальных изменений и фокальном сегментарном гломерулосклерозе.

Для цитирования: Руденко Е.В., Томилина Н.А., Захарова Е.В. Применение циклоспорина а для лечения нефротических типов хронических гломерулонефритов - болезни минимальных изменений и фокального сегментарного гломерулосклероза. Нефрология и диализ. 2015. 17(2):156-172. doi:

Весь текст

Ключевые слова: болезнь минимальных изменений, фокально-сегментарный гломерулосклероз, нефротический синдром, циклоспорин А, подоцитопатия, синаптоподин, minimal change disease, focal segmental glomerulosclerosis, nephrotic syndrome, cyclosporine A, podocytopathy, sinaptopodin

Список литературы:

1. Батюшин М.М., Повилайтите П.Э. «Клиническая нефрология». Руководство. Элиста. «Джангар», 2009. 682 с.
2. Бикбов Б.Т., Томилина Н.А. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998-2011 гг. (Отчет по данным Российского регистра заместительной почечной терапии. Часть первая). Нефрология и диализ. 2014. 16(1): 11-127.
3. Бобкова И.Н., Чеботарева Н.В., Еськова О.А., Козловская Л.В. Экскреция с мочой маркеров подоцитарной дисфункции у больных хроническим гломерулонефритом. Нефрология и диализ. 2013. 15(4): 263-268.
4. Детская нефрология. Под редакцией Э. Лоймана, А.Н. Цыгина, А.А. Саркисяна. М.: Литтерра, 2010. 416 с.
5. Захарова Е.В., Бирюкова Л.С. Роль циклоспорина в лечении идиопатического гломерулонефрита и волчаночного нефрита. Нефрология и диализ. 2010. 12(2): 126-141.
6. Иммуносупрессия при трансплантации солидных органов. Под ред. С.В. Готье. М.: Тверь. ООО Изд-во Триада, 2011. 472 с.
7. Козловская Л.В. Хронический гломерулонефрит: аргументы в пользу применения циклоспорина. Клиническая нефрология. 2010. 3: 56-61.
8. Комарова О.В., Матвеева М.В., Цыгин А.Н., Леонова Л.В., Тимофеева А.Г. Эффективность и безопасность пролонгированной терапии циклоспорином детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии. 2010. 9(4): 155-159.
9. Комарова О.В., Цыгин А.Н., Леонова Л.В. и др. Терапия циклоспорином А у детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии. 2009. 8(5): 93-97.
10. Краснова Т.Н., Тареева И.Е., Шилов Е.М. и др. Сандиммун в лечении хронического гломерулонефрита с нефротическим синдромом. Тер арх. 1995. 69(6): 21-23.
11. Мейл Д. Иммунология. Пер.с англ. М: Логосфера, 2007. 568 с.
12. Мухин Н.А., Тареева И.Е., Краснова Т.Н. и др. Лечение нефротической формы хронического гломерулонефрита сандиммуном (циклоспорином А). Тер арх. 1995. 67(8): 13-15.
13. Нефрология: Руководство для врачей. Под редакцией И.Е. Тареевой, М.: Медицина, 2000. 688 с.
14. Нефрология. Национальное руководство. Под ред. Н.А. Мухина. М.: ГЭОТАР-Медиа, 2009. 716 с.
15. Нефрология. Учебное пособие для послевузовского образования. Под ред. Е.М. Шилова. М.: ГЭОТАР-Медиа, 2010. 712 с.
16. Очерки клинической трансплантологии. Под ред. С.В. Готье. Изд. Триада, 2009. 360 с.
17. Руководство по трансплантации почки. Под ред. Габриель М. Данович. Пер. с англ., под ред. Я.Г. Мойсюка. Изд. 3-е. Тверь: ООО «Издательство «Триада», 2004. 472 с.
18. Смирнов А.В., Добронравов В.А., Неворотин А.И. и др. Гипергомоцистеинемия усугубляет повреждения нефрона при экспериментальной хронической почечной недостаточности. Нефрология. 2005. 9(4): 67-74.
19. Смирнов А.В., Добронравов В.А., Неворотин А.И. и др. Гомоцистеин вызывает повреждения не только клубочкового, но и канальцевого отдела нефрона. Нефрология. 2005. 9(3): 81-87.
20. Чеботарева Н.В., Непринцева Н.В., Еськова О.А. и др. Определение уровня в моче маркеров повреждения и факторов самозащиты подоцитов у больных хроническим гломерулонефритом. Клиническая нефрология. 2013. 4: 33-37.
21. Чеботарева Н.В., Бобкова И.Н., Козловская Л.В., Цопанова З.Г. Оценка дисфункции подоцитов по степени нефринурии при протеинурических формах хронического гломерулонефрита. Тер. Архив. 2011. 6: 18-23.
22. Abe K., Miyazaki M, Kiji T. et al. Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidnеy Int. 2001. 60 (1): 137-146.
23. Alexopoulos E, Papagianni A, Tsamelashvili M et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006. 21 (11): 3127-3132.
24. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonehpritis type II (dense deposit disease ): an update. J Am Soc Nephrol. 2005. 16: 1392-1403.
25. Asanuma K, Yanagida - Asanuma E, Faul C et al. Synaptopodin orchestrates actin organization and cell motility via rеgulation of RhoA signalling. Nat Cell Biol. 2006. 8(5): 485-491.
26. Asanuma K, Kim K, Oh J et al. Synaptopodin regulates the actin -bundling activity of alpha -actinin in an isoform-specific manner. J Clin Invest. 2005. 115 (5): 1188-1198.
27. Austin HA, Illei GG, Braun MJ.et al. Randomized controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am Soc Nephrol. 2009. 20(4): 901-911.
28. Banas MC, Banas B, Hudkins KL et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol. 2008. 19(4): 704-713.
29. Baran D., Vendeville B., Vial M.C et al. Effect of cyclosporine A on mercury-induced autoimmune glomerulonephritis in the Broun Norway rat. Clin. Nephrol. 1986. 25 (Suppl 1): S175-S180.
30. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. J Am Soc Nephrol. 2007. 2(3): 529-542.
31. Beck LH Jr, Boneio RG, Lmbeau G. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Eng J Med. 2009. 361(1): 11-21.
32. Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explane its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol. 2010. 25(7): 1197 -1199.
33. Bram RJ , Hung DT , Martin PK et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993. 13(8): 4760-4769.
34. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2008. 16(3): CD003233.
35. Braun N., Schmutzler F., Lange C et al. Immunosupressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst. Rev. 2008(3): CD003233.
36. Braun W, Kallen j , Mikol V et al. Three-demensional structure and actions of immunosuppressants and their immunophilins. FASEB J. 1995. 9(1): 63-72.
37. Brenner B.M. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest. 2002. Dec. 110(12): 1753-8.
38. Bright R. Reports of medical cases, selected with a view of illustrating the symptoms and cure of diseases by a reference to morbid anatomy. London, 1827.
39. Burgess E. Management f focal segmental glomerulosclerosis: evidence-based recommendation. Kidney Int. Suppl. 1999. 70: 26-32.
40. Calne R.Y., White D.J.G.,Thiru S. et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978. 2: 1323-1327.
41. Calne R.Y, Rolles K, White D.J. et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979. 2(8151): 1033-1036.
42. Cameron J.S. Focal segmental glomerulosclerosis in adults. Nephrol.Dial.Transplant. 2003. 18(Suppl. 6): vi45-vi51.
43. Carraro М, Caridi G, Bruschi M et al. Serum glomerular permeability activity in patient with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002. 13(7): 1946-1952.
44. Castellino F, Heuser J, Marchetti S. et al. Glucocorticosteroid stabilisation of actin filaments: a possible mechanism for inhibition of corticotropin release. Proc Natl Acad Sci USA 1992. 89(9): 3775-3779.
45. Cattran D, Neogi T, Sharma R et al. Serial estimates of serum permeability activity and clinical correlates in patient with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol. 2003. 14(2): 448-453.
46. Cattran D.C.,Appel G.B.,Herbert L.A et al. A randomizes trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999. 56 (6): 2220-2226.
47. Cattran D.C, Alexopoulos E, Heering P et al. Cyclosporinin idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007. 72(12): 1429-1447.
48. Cattran D.C, Appel G.B, Herbert LA et al. A randomized trial of cyclosporine in patient with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999. 56 (6 ): 2220-2226.
49. Cattran DC, Appel GB, Herbert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001. 59(4): 1484-1490.
50. Cattran DC., Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J Kidney Dis. 1998. 32: 72-79.
51. Charbit M, Gubler MC, Dechaux M et al. Cyclosporin therapy in patient with Alport syndrome. Pediatr Nephrol. 2007. 22(1): 57-63.
52. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009. 111(2): 9-15.
53. Clardy J. The chemistry of signal transduction. Proc Natl Acad Sci. USA 1995. 92 (1): 56-61.
54. Couser WG, Nangaku M. Cellular and molecular biology of membranous nephropathy. J Nephrol. 2006. 19(6): 699-705.
55. Craham RC Jr, Karnovsky MJ. Glomerular permeability. Ulrastructural cytochemical studies using peroxidases as protein tracers. J Exp Med. 1966. 124(6): 1123-1134.
56. D’Agati VD. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal mdels (a play in five acts). Kidney Int. 2008. 73(4): 399-406.
57. Doleris L.M., Hill G.S., Chedin P.et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int. 2000. Vol. 58: 1851-1558.
58. Doublier S, Ruotsalainen V, alvidio G et al. Nephrin redustribution on podocytes in a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol. 2001. 158 (5): 1723-1731.
59. Eguchi A., Takei T., Yoshida T. et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal change nephrotic syndrome. Nephrol.Dial.Transplant. 2010. 5(1): 124-129.
60. Ehrich J.H., Pape L., Schiffer M. Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis: an update of treatment options in children. Paediatr.Drugs. 2008. 10(1): 9-22.
61. Ehrich JH , Geerlings C , Zivicnjak M et al. Steroid- resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007. 22 (8 ): 2183-2193.
62. El-Husseini A., El-Basuony F., Mahmoud I.et al. Long-term effects of cyclosporine in children with idiopathic nephrothic syndrome: a single-centre experience. Nephrol.Dial.Transplantant. 2005. 20(11): 2433-2438.
63. ERA-EDTA Registry: ERA-EDTA Registry 2011 Annual Report. Academic Medical Center, Amsterdam, The Netherlands, 2013. 131 p.
64. Farguhar MG, Palade GE. Glomerular permeability. II. Ferritin transfer across the glomerular capillary wall in nephrotic rats. J Exp Med. 1961. 114: 699-716.
65. Faul C, Asanuma K, Yanagida -Asanuma E. et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 2007. 17(9): 428-437.
66. Faul C, Donnell M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine. A.Nat Med. 2008. 14(9): 931-938.
67. Feehally J, Flogege J., Johnson R. Comprehensive Clinical Nephrology 3 rd Edition Elsevier, 2007. Р. 181-208.
68. Filler G. How should microemulsified cyclosporine A (Neoral) therapy in nephritic syndrome be monitored? Nephrol.Dial.Transplant. 2005. 20: 1032-1034.
69. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007. 27(2): 195-207.
70. Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl. 2000. 75: S15-21.
71. Frassinetti Castelo Branco Camurca Fernandes P., Bezzera Da Silva G.Jr.,De Sousa Barros F.A.et al. Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17cases and literature review. J.Nephrol. 2005. 18(6): 711-720.
72. Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppressant. FASEBJ. 1994. 8(6): 391-400.
73. Galat A, Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.Cell Mol Life Sci. 2010. 67(20): 3467-3488.
74. Gallay PA. Cyclosporin inhibitors. Clin Liver Dis. 2009. 13(3): 403-417.
75. Gellerman J, Stefanidiis CJ, Mitsioni A et al. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol. 2010. 25(7): 1285-1289.
76. Glassock RJ. Human idiopathic membranous nephropathy - a mystery solved? N Eng J Med. 2009. 361 (1): 81-83.
77. Goumenos D.S., Tsagalis G., El Nahas A.M. et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron.Clin. Pract. 2006. 104(2): c 75-82.
78. Goumenos DS, Katopodis KP, Passadakis P et al. Corticosteroids and cyclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.Am J Nephrol 2007. 27(3): 226-231.
79. Gunn H.C., Ryffel B. Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine. Clin. Nephrol. 1986. 25 (Suppl 1): S189-S192.
80. Hamasaki Y., Yoshikawa N., Hattori S.et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2009. 24(11): 2177-2185.
81. Hara M., Yanagihara T., Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 2001. Nov. 89(3): 342-7.
82. Hartleben B, Godel M, Meyer -Schwesinger C. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010. 120(4): 1084-1096.
83. Harvey SJ, Jarad G, Cunninham J et al. Disruption of glomerular basement membrane charge through podocytespecific mutation of agrin does not alter glomerular permslectivity. Am J Pathol. 2007. 171(1): 139-152.
84. Heidet L, Bongers EM, Sih M et al. In vivo expression of putative LMX1B targets in nail-patella syndrome kidneys. Am J Pathol. 2003. 163 (1): 145-155.
85. Hen JC, Husian M, Sunamoto M et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stst3 and MARK1, 2 pathways. J Clin Invest. 2004. 114(5): 643-651.
86. Hotta O., Inoue C.N., Miybayashi S. et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001.Vol. 59: 1236-1243.
87. Ina K, Kitamura H, Tatsukawa S et al. Glomerular podocyte endocytosis of the diabetic rat. J Electron Microsc (Tokio) 2002. 51 (4): 275-279.
88. Ittel T.H.,Clasen W., Fuhs M.et al. Long-term cyclosporine A treatment in adults with minimal change nephrotic syndrome of focal segmental glomerulosclerosis. Clin.Nephrol. 1995. 44(3): 156-162.
89. Jain KK. Challenges of drug discovery for personalized medicine. Curr Opin Mol Ther. 2006. 8 (6): 487-492.
90. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol. 1980. 86(2): 688-693.
91. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Suppl. 2/issue 2/June 2012.http// www.kidney-international.org.
92. Kestila M, Lenkkeri U , Munnika M et al. Positionally cloned gene for a novel glomerular protein-nephrin is mutated in congenital nephrotic syndrome. Mol Cell. 1998. 1(4): 575-582.
93. Kim YH, Goyal M, Kurnit D et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN -treated rat. Kidney In. 2001. 60(3): 957-968.
94. Kiomasu T, Snibata M, Kurosu H et al. Cyclosporin a treatment for membranoproloferative glomerulonephritis type II. Nephron 2002. 91 (3):509-511.
95. Kitiyakara C., Eggers P., Kopp J.B. Twenty one-year trend in ESRDS due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004. 44: 815-825.
96. Korbet SM, Schwartz MM, Lewis E.J. Primary focal segmental glomerulosclerosis. clinical course and response to therapy. Am. J Kidney Dis. 1994. 23: 773-783.
97. Korgaonar SN , Feng X , Ross MD et al. HIV-1 up regulates VEGF in podocytes. J AM Soc Nephrol. 2008. 19(5): 877-883.
98. Koukouritaki SB, Lianos EA. Glucocorticoid achieve effect on human mesangial cell cytoskeleton proteins. J Lab Clin Med. 1999. 133(4): 378-383.
99. Kretzler M. Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol. 2005. 16(10): 2830-2832.
100. Kriz W, Hackenthal E, Nobilling R et al. A role for podocytes to counteract capillary wall distention. Kidney Int. 1994. 45(2): 369-376.
101. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002. 57(4): 189-195.
102. Lai KN, Leung JC, Chan LY et al. Podocyte injury induced by mesangial -derived cytokines in Ig A nephropathy. Nephrol Dial Transplant 2009. 24(1): 62-72.
103. Lennon R., Singh A., Welsh GI, et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nophrol. 2008. 19: 2140 - 2149.
104. Li Y, Kang Ys, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008. 172 (2): 299-308.
105. Liberman K.V., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant focal segmental glomeulosclerosis in children. J.Am.Soc.Nehrol. 1996. 7(1): 56-63.
106. Liu J., Farmer J.D., Lane W.S. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complex. Cell. 1991. 66(4): 807-815.
107. Li H, Zhang L, Rao A, Harrison SC, Hogan PG. Structure of calcineurin in complex with PVIVIT peptide: portrait of a low affinity signalling interaction. J Mol Biol. 2007. 369: 1296-1306.
108. Lu TC, He JC, Klotman PE. Podocytes in HIV-associated nephropathy. Nephron Clin Pract. 2007. 106 (2): 67-71.
109. Mak S.K., Short C.D., Mallick N.P. Long-term outcome of adult-onset minimal change nephropathy. Nephrol.Dial.Transplant. 1996. 11: 2192-2230.
110. Malina M, Cinek O, Janda J et al. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol. 2009. 24(10): 2051-2053.
111. Massella L, Muda AO, Legato A et al. Cyclosporine A treatment in patient with Alport syndrome: a single-center experience. Pediatr Nephrol. 2010. 25 (7): 1269-1275.
112. Matheison PW. Podocyte actin in health, disease and treatment. Nephrol Dial Transplant 2010. 25(6): 1772-1773.
113. Matheison PW. Proteinuria and immunity - an overstated relationship? N Engl J Med. 2008. 359(23): 2492-2494.
114. Matsumoto H., Nakao T., Okado T et al. Initial remission-inducting effect of very low-dose cyclosporine monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin.Nephrol. 2001. 55: 143-148.
115. Matsumoto H., Nakao T., Okado T et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome.Intern. Med. 2004. 43(8): 668-673.
116. McCarthy ET., Sharma M., Savim VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc 2019. 5: 2115 - 2122.
117. Meryrier A., Noel L.H., Auriche P., Callard P. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome Collaborative Group of the Society de Nephrologie. Kidney Int. 1994. 45(5): 1446-1456.
118. Meyer TW , Bennet PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999. 42(11): 1341-1344.
119. Meyrier A. Antiproteinuric and immunological effects of cyclosporine A in the treatment of glomerular diseases. Nephrol Dial Transplant. 1992. 7 Suppl 1: 80-84.
120. Meyrier A., Condamin M.C., Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporine A minimal change disease and focal segmental glomerulosclerosis. Collaborative Group of Societe de Nephrology. Clin Nephrol. 1991. 35(Suppl 1): S37-S42.
121. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2009 Mar. 10(4): 615-28.
122. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009. 76 (5): 487-491.
123. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol. Dial. Transplant. 2003. 18 (Suppl. 6): vi79-vi86.
124. Meyrier A., Simon P., Perret G., Condamin-Meyrier M.C Remission of idiopathic nephrotic syndrome after treatment with cyclosporine. Ann.Br.Med J. 1986. 292: 789-792.
125. MeyrierA., Simon P. Treatment of cortico-resistant idiopathic nephritic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis. Adv. Nephrol. Necker Hosp. 1988. 17: 127-150.
126. Miao J, Fan Q, Cui Q et al. Newly identified cytoskeletal components are associated with dynamic changes of podocyte foot processes. Nephrol Dial Transplant. 2009. 24(11): 3297-3305.
127. Michaud J-L, Lemieux LI, Dube M, et al. FSGS in mice with podocyte-specific expression of mutant alfa-actinin-4. J Am Soc Nephrol. 2003. 14: 1200-1211.
128. Morigi M, Buelli S, Angioletti S et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005. 166 (5): 1309-1320.
129. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010. 77 (7): 571-580.
130. Mundel P., Shankland S.J. Podocyte biology and response to injury.Am. J.Soc.Nephrol. 2002. Vol. 13: 3005-3015.
131. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005. 16(5): 1195-1204.
132. Ogawa H , Kameda H, Amano K. et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010. 19(2): 162-169.
133. Patrakka J, Truggvason K. New insigts into the role of podocytes in proteinuria. Nat Rev Nephrol. 2009. 5(8): 463-468.
134. Plank C, Kalb V, Hinkes B et al. Cyclosporine A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome - a randomized controlled multicenter trial by the Arbeitsgemeinscaft fur Pediatrische. Nephrologie. Pediatr Nephrol. 2008. 23 (9): 1483-1493.
135. Ponticelli С., Rizzoni G., Edefoni A., et al. A randomized controlled trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993. 43: 1377-1384.
136. Ponticelli C.,Edefonti A., Ghio I. et al. Cyclosporin versus Cyclophosphamide for patients with steroid-dependent idiopathic nephrotic syndrome: a multicenter randomized controlled trial. Nephrol. Dial. Transpl. 1993. 8: 1326-1332.
137. Pritula A., Lijima K., Kamei K. et al. Rituximab in refractory nephrotic syndrome. Pediatric Nephrol. 2010. 23: 461-168.
138. R. Coppo. Different Targets for Treating Focal Segmental Glomerulosclerosis In: New Insights into Glomerulonephritis. Ed N.Chen. KARGER. 2013.
139. Ranson RF, Lam NG, Hallet MA. et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 2005. 68(6): 2473-2483.
140. Rasce F.M., Keller F., Kunze G. et al. Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome. Clin.Nephrol. 2007. 67(5): 285-292.
141. Reiser J, Gupta V, Kistler A.D. Toward the development of podocyte-specific drugs. Kidney Int. 2010. 77(8): 662-668.
142. Reiser J, von Gersdorff G. Loos M. et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004. 113(10): 1390-1397.
143. Ren H., Shen P., Li Х. et al. Treatment and Prognosis of Primary Focal Segmental Glomerulosclerosis. In: New Insights into Glomerulonephritis. Contrib.Nephrol. Ed N.Chen. Basel. Karger, 2013. 181. Р. 109-118.
144. Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol. 2010. 21 (4): 564-569.
145. Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schenlein glomerulonephritis. Pediatr Nephrol. 2003. 18 (11): 1138-142.
146. Rossi M, Morita H, Sormunen R et al. Heperan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J. 2003. 22(2): 236-245.
147. Ruf RG, Lichtenberger A, Karle SM et al. Patients with mutations in NPHS2 (podocin) do not response to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004. 15(3): 722-732.
148. Rydel J.J., Korbet S.M., Borok R.Z., Schwartz M.M Focal segmental glomerular sclerosis in adults: presentations, course, and response to treatment. J.Am.Soc.Nehrol. 1995. 25: 534.
149. Saran AM , Yuan H, Takeuchi E et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int. 2003. 64(6): 2072-2078.
150. Savin VJ, Sharma R, Lovell H.B. et al. Measurement of albumin reflection coefficient with isolated rat glomeruli. J. Am. Soc. Nephrol. 1992. 3(6): 1260-1269.
151. Savin VJ, Sharma R, Sharm M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl Med. 1996. 334(14): 873-883.
152. Savin VJ., Sharma M. Plasma “factors” in reccurent nephrotic syndrome after kidney transplantation: causes of consequences of glomerular injury? Am I Kidney Dis. 2009. 54: 406-409.
153. Schiffer M1, Bitzer M, Roberts I et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001 Sep. 108(6): 807-16.
154. Schijver G, Assmann KJ, Wetzels JF et al. Cyclosporin A reduces albuminuria in experimental anti-GBM nephritis independently from changes in GRF. Nephrol Dial Transplant. 1995. 10 (7): 1149-1154.
155. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974. 2 (7880): 556-560.
156. Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006. 69 (12): 2131-2147.
157. Sheashaa H., Mahmoud I., El-Basuony F. et al. Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? A long-term efficacy and safety study. Int. Urol. Nephrol. 2007. 39(3): 923-928.
158. Shin I , Park JM, Shin YH et al. Cyclosporin A therapy for severe Henoch-Schenlein nephritis with nephrotic syndrome. Pediat Nephrol. 2005. 20(8): 1093-1097.
159. St John PL, Abrahamson DR. Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int. 2001. 60(3): 1037-1046.
160. Suthanthiran M., Strom T.B. Immunoregulatory drugs: mechanistic basis for use in organ transplantation. Pediatr. Nephrol.1997. 11(5): 651-657.
161. Tajima K, Amakawa R, Ito T et al. Immunomodulatory effects of cyclosporin A on human peripherial blood dendritic cell subsets. Immunology. 2003. 108 (3): 321-328.
162. ThaissF., Mihatsch M.J.,Bastford S.et al. Effect of Cyclosporine on in situ immune complex glomerulonephritis. Clin. Nephrol. 1986. 25 (Suppl 1.): S181-S185.
163. Thompson AW. The spectrum of action of new immunosupressive drugs. Clin Exp Immunl. 1992. 89(2): 170-173.
164. Tipping PG. Are podocytes passive or provocative in proteinuric glomerular pathology. J. Am Soc Nephrol. 2008. 19(4): 651-653.
165. Topham PS, Haydar SA , Kuphal R. et al. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesion. Kidney Int 1999. 55(5): 1763-1775.
166. Torbjornsdotter TB, Perrin NE, Jaremko GA et al. Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol. 2005. 20(6): 750-758.
167. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectvity. Curr Opin Nephron Hypertens. 2001. 10(4): 543-549.
168. Tse K.C., Lam M.E., Yipo P.S. et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol. Dial. Transplant. 2003. 18: 1316-1320.
169. Tune B.M., Mendoza S.A. Treatment of the idiopathic nephritic syndrome: regimens and outcomes in children and adults. J. Am. Soc. Nephrol. 2001. 12: 44-47.
170. U S Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013).
171. Van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerlopathies. Kidney Int. 2004. 66(5): 1901-1906.
172. Wada T, Pippin JW, Marshall CB et al. Dexametasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins J Am Soc Nephrol. 2005. 16(9): 2615-2625.
173. Wada T., Pippin J.W., Nangaku M. et al. Dexamethasone’s prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation. Nephron Exp Nephrol. 2008. 109(1): 8-19.
174. Wagrowska -Danilewicz M, Danilewicz M. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulsclerosis. Nephrologia. 2007. 27(6): 710-715.
175. Waldman M.,Crew R.J., Valery A. еt al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin. J. Am. Soc. Nephrol. 2007. 2: 445-453.
176. Waldo F.B., Kohaut E.C. Therapy of focal segmental glomerulosclerosis with cyclosporine. A. Pediatr. Nephrol. 1987. 1(2): 180-182.
177. Waldo F.B., Benfield M.R., Kohaut E.C et al. Therapy of focal segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr. Nephrol. 1998. 1(5): 397-400.
178. Wei C., Saleem M., Goes N. Reiser J. Soluble urokinase receptor is a circulating glomerular disease recurrence factor. J Am Soc. Nephrol. 2008. 19: 10-3A.
179. Weins A, Kenlan P, Herbert S, et al. Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Neprol. 2005. 16: 3694-3701.
180. Wharran BL, Goyal M, Wigins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005. 16(10): 2941-2952.
181. Zietse R, Wenting GL, Kramer et al. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Cln Sci ( Lond). 1992. 82(6): 641-650.
182. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007. 71(12): 1205-1214.
183. Xing CY , Saleem MA, Coward RJ. et al. Direct effects of dexametasone on human podocytes. Kidney Int. 2006. 70(6): 1038-1045.
184. Yamagata K., Muro K., Usui J. et al. Mitochondrial DNA mutations in focal segmental glomerulosclerosis lesions. J. Am. Soc. Nephrol. 2002. Vol. 13: 1816-1823].
185. Yan K , Kudo A, Hirano H et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int. 1999. 56(1): 65-73.
186. Yanagida-Asanuma E, Asanuma K, Kim K. et al. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53: Mena signaling complexes in kidney podocytes. Am J Pathol. 2007. 171(2): 415-427.
187. Yoshiawa N, Ito H, Akamatsu R et al. Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med. 1986. 110(5): 394-398.
188. Yuan H, Takeuchi E, Taylor GA et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol. 2002. 13(4): 946-956.

Другие статьи по теме

• Опыт применения циклоспорина А в лечении идиопатического фокального сегментарного гломерулосклероза
• Иммунокостная дисплазия Шимке: мини-обзор литературы, серия клинических случаев и опыт ведения после трансплантации почки
• Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней
• Качество жизни и ассоциированные клинические факторы при иммуноопосредованных гломерулопатиях